Department of Pulmonology & Respiratory Medicine, Faculty of Medicine, Hasanuddin University/Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia.
Department of Pulmonology & Respiratory Medicine, Faculty of Medicine, Hasanuddin University/Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia.
Gac Sanit. 2021;35 Suppl 2:S530-S532. doi: 10.1016/j.gaceta.2021.10.085.
The high mortality rate in Coronavirus Disease (COVID-19) patients is associated with their comorbid conditions. Therefore, it is important to identify risk factors associated with poor outcomes among COVID-19 patients. The aims of this study were to find out the comorbidities in case of death due to COVID-19.
The design of this study was a retrospective descriptive method with a confirmed COVID-19 patient on hospitalized at Dr. Wahidin Sudirohusodo Hospital from March to September 2020. Ethics Council recommendation number: 357/UN4.6.4.5.31/PP36/2020.
A total of 454 patients were included of this study. 78 (17.18%) patients death due to COVID-19, consisting of 52 (66.67%) male and 26 (33.33%) female. Range of ages between 18 and 85 years. The highest mortality rate occurred in the age group ≥60 years (35; 51.47%), followed by the age group of 45-59 years (33; 48.53%), and the age group of <45 years (10; 12%). The prevalent comorbidity was hypertension (42.31%), cardiovascular disease (30.77%), diabetes (28.21%), chronic kidney disease (23.08%), malignancy (15.38%), obesity (15.38%), chronic liver disease (7.69%), chronic respiratory disease (6.41%), immune related disease (3.85%), and non-traumatic cerebral infarction (3.85%). 41 (52.56%) patients reported having two or more comorbidities, and 37 (47.44%) only has one comorbidity. Elevated neutrophil-to-lymphocyte ratio (NLR) ≥3.13 was seen in the majority of patients (68; 87.18%). The mean value of NLR was 20.94.
Hypertension, cardiovascular disease, and diabetes were the most common comorbidity in patients death due to COVID-19. More than half of the patients had two or more comorbidities.
新冠肺炎（COVID-19）患者的高死亡率与合并症有关。因此，识别 COVID-19 患者不良预后的相关风险因素非常重要。本研究的目的是找出 COVID-19 死亡病例的合并症。
本研究设计为回顾性描述性方法，纳入 2020 年 3 月至 9 月期间在 Wahidin Sudirohusodo 医院住院的确诊 COVID-19 患者。伦理委员会建议编号：357/UN4.6.4.5.31/PP36/2020。
本研究共纳入 454 例患者。78 例（17.18%）COVID-19 患者死亡，其中 52 例（66.67%）为男性，26 例（33.33%）为女性。年龄在 18-85 岁之间。死亡率最高的是年龄≥60 岁组（35 例；51.47%），其次是 45-59 岁组（33 例；48.53%）和<45 岁组（10 例；12%）。最常见的合并症是高血压（42.31%）、心血管疾病（30.77%）、糖尿病（28.21%）、慢性肾脏病（23.08%）、恶性肿瘤（15.38%）、肥胖症（15.38%）、慢性肝脏疾病（7.69%）、慢性呼吸道疾病（6.41%）、免疫相关疾病（3.85%）和非创伤性脑梗死（3.85%）。41 例（52.56%）患者报告有两种或两种以上合并症，37 例（47.44%）仅有一种合并症。大多数患者的中性粒细胞与淋巴细胞比值（NLR）≥3.13（68 例；87.18%）升高。NLR 的平均值为 20.94。
高血压、心血管疾病和糖尿病是 COVID-19 死亡患者最常见的合并症。超过一半的患者有两种或两种以上的合并症。
